Has Robin Reyes received payments from drug or device companies?

Yes. Drug and device makers reported $4,097 in general payments to Robin Reyes across 172 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Robin Reyes did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Robin Reyes come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Robin Reyes

Medical · Bakersfield, CANPI 1104836931

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 172 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 50.5% of the total. 2025 is the largest year on record at $1,242, 4.0 times the $312 reported in 2021.

$4,097in general payments, 2019–2025

Across 172 payments — averaging $23.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$2K
Revance Therapeutics, Inc.$479
UCB, Inc.$395
Mayne Pharma Commercial LLC$196
Johnson & Johnson$139
GSK$112
plus $705 from 17 others

What the payments were for

Food & beverage$4,097100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	86	$2,071
Revance Therapeutics, Inc.	10	$479
UCB, Inc.	13	$395
Mayne Pharma Commercial LLC	21	$196
Johnson & Johnson	6	$139
GSK	4	$112
Biofrontera Inc.	3	$81
Sun Pharmaceutical Industries Inc.	4	$74
Botanix SB Inc	2	$60
Galderma Laboratories, L.p.	3	$57
Merz North America, Inc.	2	$52
Pfizer	2	$50
Amgen	2	$49
Novartis	2	$45
Arcutis Biotherapeutics, Inc.	2	$41
Regeneron Healthcare Solutions, Inc.	2	$39
Ortho Dermatologics, A Division Of Bausch Health US, LLC	2	$33
Journey Medical Corporation	1	$26
Verrica Pharmaceuticals Inc.	1	$22
Sanofi-aventis U.S. LLC	1	$22
LEO Pharma Inc.	1	$19
Medimetriks Pharmaceuticals, Inc.	1	$18
VYNE Pharmaceuticals Inc.	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

DAXXIFY$332
Rinvoq$246
Skyrizi$118

How this compares

$4,097 in reported general payments places this provider in the 85th percentile of 2,087 medical providers in California.

See all medical providers in California →

Other medical in Bakersfield

Geo MathewBakersfield$20K
Nicola LowreyOrange$655K
Justin LoveLoma Linda$553K
Alison GracomIrvine$467K
Jeffrey BonnaudLos Angeles$314K
Ana TorresLaguna Beach$229K
Heather ParlettRedlands$168K
David DoriguzziLancaster$166K
Deirdre MoxleyFullerton$149K
Linda RankLadera Ranch$105K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →